Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Tailored ablation with vein of Marshall for persistent atrial fibrillation ablation
Session:
Sessão de Comunicações Orais 13 – Para além do isolamento das veias pulmonares: estratégias avançadas na ablação da fibrilhação auricular
Speaker:
Mariana Rodrigues Simões
Congress:
CPC 2026
Topic:
C. Arrhythmias and Device Therapy
Theme:
05. Atrial Fibrillation
Subtheme:
05.4 Atrial Fibrillation - Treatment
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Mariana Rodrigues Simões; Tatiana Pereira dos Santos; Carolina Saleiro; João Ferreira; Patrícia Alves; Nuno Pontes; José Nascimento; Natália António; Pedro A. Sousa; Lino Gonçalves
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Arial",sans-serif">Introduction: </span></strong></span></span><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="font-family:"Arial",sans-serif">Catheter ablation is the treatment of choice in symptomatic patients with atrial fibrillation (AF) who do not respond to antiarrhythmic drug therapy, with pulmonary vein isolation (PVI) serving as the cornerstone of AF ablation. Despite advances in ablation techniques, freedom from atrial arrhythmias remains limited, particularly in patients with persistent or long-standing persistent AF.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Arial",sans-serif">Methods and purpose:</span></strong><span style="font-family:"Arial",sans-serif"> Prospective single-center, observational study of consecutive referred for catheter ablation for persistent AF ablation between August 2022 and August 2024. Patients were submitted to a tailored ablation guided by the presence of low-voltage areas. Procedural endpoints and 1-year outcomes were assessed and compared to those of a propensity score-matched (1:1 ratio) cohort of patients submitted to only PVI during the same period. All REDO procedures were excluded. The primary endpoint was defined as freedom from any atrial arrhythmia of at least 30 seconds duration, regardless of symptoms, after the 3-month blanking period. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Arial",sans-serif">Results: </span></strong><span style="font-family:"Arial",sans-serif">A total of 118 patients (71% male, mean age of 62±years) fulfilled our inclusion criteria and were included in our study, corresponding 59 to the tailored approach group and 59 propensity score-matched patients in the control group. Mean LA volume index was 45.5</span><span style="font-family:Symbol">±</span><span style="font-family:"Arial",sans-serif">13 and mean left ventricular ejection fraction was 48.1</span><span style="font-family:Symbol">±</span><span style="font-family:"Arial",sans-serif">14.51%. In the tailored group, sixty percent of patients underwent vein of Marshall ethanol infusion, which was followed by creation of a posterior mitral line; A roof line was created in 8% of patients, a posterior box in 73%, and an anterior mitral line in 27%. At 1-year follow-up, 26 patients had recurrences of sustained atrial arrhythmia: AF in 21 patients, atrial flutter in 3 patients and atrial tachycardia in the remaining 2 patients. Overall, single-procedure freedom from atrial arrhythmia after the 3-month blanking period was 78%. The risk of recurrence was significantly lower in the tailored approach group compared with the control group (13.5% vs. 30.5%, p=0.019). (Figure 1). The use of VoM ethanol infusion were associated with freedom from atrial recurrence during follow-up with a HR= 0.271 (95% CI 0.081-0.904), p=0.013. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Arial",sans-serif">Conclusion: </span></strong></span></span><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><span style="font-family:"Arial",sans-serif">A tailored approach guided by the presence of LVA was associated with a higher arrhythmia-free survival at 1-year of follow-up compared with performing PVI alone and VoM ethanol infusion was associated with a reduced risk of AF recurrence.</span></span></span></p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site